Published in JACC Cardiovasc Imaging on March 18, 2015
How to Distinguish Between Myocarditis and Sarcoidosis Based on CMR Imaging. JACC Cardiovasc Imaging (2016) 1.07
What Is the Arrhythmic Substrate in Viral Myocarditis? Insights from Clinical and Animal Studies. Front Physiol (2016) 0.92
Role of Imaging Techniques for Diagnosis, Prognosis and Management of Heart Failure Patients: Cardiac Magnetic Resonance. Curr Heart Fail Rep (2015) 0.77
The Authors Reply. JACC Cardiovasc Imaging (2016) 0.75
Can magnetic spins determine the cause of an electrical storm? JACC Cardiovasc Imaging (2015) 0.75
Chagas' heart disease: gender differences in myocardial damage assessed by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2016) 0.75
Cardiac magnetic resonance imaging and electroanatomic voltage discordance in non-ischemic left ventricle ventricular tachycardia and premature ventricular depolarizations. J Interv Card Electrophysiol (2017) 0.75
The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med (2000) 13.25
The electrocardiogram in population studies. A classification system. Circulation (1960) 11.86
Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation (1999) 11.04
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med (1997) 10.02
Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation (2006) 5.47
Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation (2003) 4.48
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 4.12
Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation (2000) 3.98
Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation (1993) 3.26
Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol (2008) 2.99
Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation (2005) 2.80
The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation . J Am Coll Cardiol (2013) 2.76
Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation (2008) 2.61
Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol (2011) 2.57
Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA (2012) 2.21
Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol (2009) 1.96
Catheter ablation for ventricular tachycardia. Circulation (2007) 1.89
Prognostic role of CMR in patients presenting with ventricular arrhythmias. JACC Cardiovasc Imaging (2013) 1.62
Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol (2003) 1.59
Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol (2011) 1.29
Utility of cardiovascular magnetic resonance in identifying substrate for malignant ventricular arrhythmias. Circ Cardiovasc Imaging (2011) 1.24
CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. JACC Cardiovasc Imaging (2013) 1.17
Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc (2013) 1.13
Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol (2012) 0.99
Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace (2011) 0.93
Predicting sudden death risk for heart failure patients in the implantable cardioverter-defibrillator age. Circulation (2003) 0.86
Factors influencing the decision to ICD implantation in survivors of OHCA and its influence on long term survival. Resuscitation (2012) 0.81
Myocardial infarction without obstructive coronary artery disease. Curr Opin Cardiol (2012) 0.81
Myocardial extracellular volume expansion and the risk of recurrent atrial fibrillation after pulmonary vein isolation. JACC Cardiovasc Imaging (2013) 2.80
Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function. Am J Cardiol (2015) 0.83
CMR and amyloid cardiomyopathy: are we getting closer to the biology? JACC Cardiovasc Imaging (2014) 0.82
Assessment of LV Myocardial Scar Before Atrial Fibrillation Ablation. JACC Cardiovasc Imaging (2015) 0.75
Entrainment mapping: Theoretical considerations and practical implementation. J Cardiovasc Electrophysiol (2017) 0.75